Literature DB >> 24787480

Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease.

J M Michot1, C Gubavu2, E Fourn2, G Maigne3, E Teicher2, A Angoulvant4, S Blanche5, O Lortholary6, A Coilly7, J C Duclos-Vallée7, M Sebagh8, C Guettier8, C Aumont9, J F Delfraissy3, O Lambotte3.   

Abstract

Amphotericin B is a powerful polyene antifungal drug used for treating systemic fungal infections and is usually administered for a short period. Side effects after prolonged use are unknown in humans. Here we report the case of a 28-year-old man suffering from chronic granulomatous disease (CGD), treated for invasive cerebral aspergillosis with liposomal amphotericin B (L-AmB) for a very long time (8 consecutive years). We describe the efficacy and safety of this treatment in the long term. Aspergillosis was kept under control as long as L-AmB therapy was maintained, but relapsed when the dose was reduced. No overt renal toxicity was noted. The patient gradually developed hepatosplenomegaly and pancytopenia. Abnormalities of bone marrow were similar to the sea-blue histiocyte syndrome. Liver biopsy showed images of nodular regenerative hyperplasia related to CGD as well as a histiocytic storage disease. We discuss the very prolonged use of L-AmB leading to the development of a lysosomal storage disease.
Copyright © 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antifungal agents; Chronic granulomatous disease; Neuroaspergillosis; Sea-blue histiocyte syndrome

Mesh:

Substances:

Year:  2014        PMID: 24787480     DOI: 10.1016/j.ijantimicag.2014.02.015

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  3 in total

1.  Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient.

Authors:  Rodrigo de Carvalho Santana; Letícia Aparecida Schiave; Alda Soares Dos Santos Quaglio; Cristiane Masetto de Gaitani; Roberto Martinez
Journal:  Mycopathologia       Date:  2017-06-27       Impact factor: 2.574

2.  Tailoring amphotericin B as an ionic liquid: an upfront strategy to potentiate the biological activity of antifungal drugs.

Authors:  Diego O Hartmann; Karina Shimizu; Maika Rothkegel; Marija Petkovic; Ricardo Ferraz; Željko Petrovski; Luís C Branco; José N Canongia Lopes; Cristina Silva Pereira
Journal:  RSC Adv       Date:  2021-04-16       Impact factor: 3.361

Review 3.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.